Tabula Rasa HealthCare Inc Q1 2022 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst : Starting with the CareVention guidance, Tom, I think you said you changed things, that you're now assuming 0.7% sequential monthly growth incentives versus the 1% you all were targeting before. Can you just give us a little bit more detail on what you think is behind that slower census growth trajectory? Tom Sims: I mean that's just what we're seeing in the business right now that's consistent with what we've seen over the last quarter. And we thought that was the best way to project it going forward. Sean Dodge: Is that a little bit of a hangover from COVID? Is that -- do you think maybe an effect of Omicron, or do you think there's something kind of structurally different?

Question: Sean Wilfred Dodge - RBC Capital Markets, Research Division - Analyst : Okay. And I know I know that you said you're not providing EBITDA guidance for the time being, but is there any help you can give us just directionally on how to think about costs within CareVention going forward? Are you working to rationalize expenses there? I know you mentioned a little bit of a reallocation of R&D from MedWise to CareVention. Are you rationalizing there, or would this be in the go-forward business? Are you continuing to invest in CareVentures, so we should expect expenses there to go up over the course of the year?